CardiAMP cell therapy - BioCardia

Drug Profile

CardiAMP cell therapy - BioCardia

Alternative Names: CardiAMP

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator BioCardia
  • Class Cell therapies; Heart failure therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Heart failure
  • Phase I Myocardial infarction
  • No development reported Ischaemic heart disorders

Most Recent Events

  • 29 Dec 2016 Phase-III clinical trials in Heart failure in USA (Intracoronary)
  • 14 Dec 2016 BioCardia has patent protection for CardiAMP® cell therapy in USA
  • 22 Feb 2016 Efficacy data from the phase I ALSTER-HELIX trial in Myocardial Infraction released by BioCardia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top